company background image

Soligenix NasdaqCM:SNGX Stock Report

Last Price


Market Cap







23 Sep, 2022


Company Financials +
SNGX fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health5/6

SNGX Stock Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

Soligenix Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Soligenix
Historical stock prices
Current Share PriceUS$0.51
52 Week HighUS$1.20
52 Week LowUS$0.38
1 Month Change-38.87%
3 Month Change-7.10%
1 Year Change-50.50%
3 Year Change-45.44%
5 Year Change-77.25%
Change since IPO-99.66%

Recent News & Updates

Sep 12

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Soligenix (NASDAQ:SNGX) is trading 3.2% higher after the U.S. Food and Drug Administration awarded a $2.6M grant to support a study of expanded HyBryte treatment to treat T-cell lymphoma, including at-home usage. HyBryte is a skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin disease and cancer. The Orphan Products Development grant, totaling $2.6M over four years, was awarded to an academic institution that was a leading enroller in Soligenix's successful Phase 3 study in the treatment of early stage CTCL. The treatment is expected to launch in Q4.

Sep 06

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Clinical-stage biotech Soligenix, Inc. (NASDAQ:SNGX) announced Tuesday that the FDA had awarded a $2.6M grant to support studies for its experimental therapy HyBryte for expanded treatment in early-stage cutaneous T-Cell Lymphoma (CTCL). A photodynamic therapy, HyBryte, also known as SGX301, uses safe, visible light for activation. CRCL is a form of non-Hodgkin's lymphoma, a cancer involving white blood cells, which are essential for the body's immune function. The FDA's four-year Orphan Products Development grant was awarded to an academic institution that led the enrollment in the Phase 3 FLASH trial for the candidate in the treatment of early CTCL, SNGX said. The 50-patient trial for HyBryte will be conducted as an open-label study involving the highest enrolling clinical centers that took part in the FLASH study. The trial, named RW-HPN-MF-01, is expected to start in Q4 2022. Read more on data from the FLASH trial.

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Aug 12

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Soligenix press release (NASDAQ:SNGX): Q2 GAAP EPS of -$0.06 beats by $0.03. Revenue of $0.4M (+100.0% Y/Y) beats by $0.2M. As of June 30, 2022, the Company's cash position was approximately $20.2 million. Shares +5% PM.

Shareholder Returns

SNGXUS BiotechsUS Market

Return vs Industry: SNGX underperformed the US Biotechs industry which returned -30.9% over the past year.

Return vs Market: SNGX underperformed the US Market which returned -21.6% over the past year.

Price Volatility

Is SNGX's price volatile compared to industry and market?
SNGX volatility
SNGX Average Weekly Movement9.3%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.8%

Stable Share Price: SNGX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: SNGX's weekly volatility (9%) has been stable over the past year.

About the Company

198714Christopher Schaber

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.

Soligenix Fundamentals Summary

How do Soligenix's earnings and revenue compare to its market cap?
SNGX fundamental statistics
Market CapUS$21.87m
Earnings (TTM)-US$15.03m
Revenue (TTM)US$878.55k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SNGX income statement (TTM)
Cost of RevenueUS$687.48k
Gross ProfitUS$191.07k
Other ExpensesUS$15.22m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.35
Gross Margin21.75%
Net Profit Margin-1,710.45%
Debt/Equity Ratio234.8%

How did SNGX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is SNGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNGX?

Other financial metrics that can be useful for relative valuation.

SNGX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13.6x
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SNGX's PS Ratio compare to its peers?

SNGX PS Ratio vs Peers
The above table shows the PS ratio for SNGX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average39.5x
ONVO Organovo Holdings
NHWK NightHawk Biosciences
AGTC Applied Genetic Technologies
SNGX Soligenix

Price-To-Sales vs Peers: SNGX is good value based on its Price-To-Sales Ratio (24.9x) compared to the peer average (39.5x).

Price to Earnings Ratio vs Industry

How does SNGX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: SNGX is expensive based on its Price-To-Sales Ratio (24.9x) compared to the US Biotechs industry average (13x)

Price to Sales Ratio vs Fair Ratio

What is SNGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNGX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio24.9x
Fair PS Ratio29.5x

Price-To-Sales vs Fair Ratio: SNGX is good value based on its Price-To-Sales Ratio (24.9x) compared to the estimated Fair Price-To-Sales Ratio (29.5x).

Share Price vs Fair Value

What is the Fair Price of SNGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SNGX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SNGX's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Future Growth

How is Soligenix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNGX's revenue (117.7% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: SNGX's revenue (117.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNGX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Soligenix performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SNGX is currently unprofitable.

Growing Profit Margin: SNGX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: SNGX is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.

Accelerating Growth: Unable to compare SNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: SNGX has a negative Return on Equity (-357.29%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Soligenix's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SNGX's short term assets ($20.8M) exceed its short term liabilities ($8.8M).

Long Term Liabilities: SNGX's short term assets ($20.8M) exceed its long term liabilities ($8.3M).

Debt to Equity History and Analysis

Debt Level: SNGX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SNGX's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNGX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SNGX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 17% each year.

Discover healthy companies


What is Soligenix current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SNGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SNGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SNGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNGX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SNGX has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Christopher Schaber (56 yo)





Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

CEO Compensation Analysis

Compensation vs Market: Christopher's total compensation ($USD687.41K) is about average for companies of similar size in the US market ($USD776.35K).

Compensation vs Earnings: Christopher's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: SNGX's management team is seasoned and experienced (8.2 years average tenure).

Board Members

Experienced Board: SNGX's board of directors are seasoned and experienced ( 13.2 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqCM:SNGX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 May 22BuyUS$8,866Christopher SchaberIndividual20,000US$0.44
18 May 22BuyUS$4,000Richard StraubeIndividual8,000US$0.50
17 Dec 21BuyUS$5,179Christopher SchaberIndividual7,000US$0.74
15 Dec 21BuyUS$7,819Jonathan GuarinoIndividual11,000US$0.71
14 Dec 21BuyUS$7,269Christopher SchaberIndividual10,000US$0.73

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.

Top Shareholders

Top 25 shareholders own 7.8% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
The Vanguard Group, Inc.
1,640,245$832.3k-0.17%no data
First Wilshire Securities Management, Inc.
Geode Capital Management, LLC
321,838$163.3k7.52%no data
Knoll Capital Management
Christopher Schaber
90,095$45.7k0%no data
State Street Global Advisors, Inc.
72,964$37.0k54.03%no data
Plante & Moran Financial Advisors
IHT Wealth Management LLC
70,150$35.6k0%no data
Renaissance Technologies LLC
52,800$26.8k45.45%no data
Northern Trust Global Investments
51,116$25.9k0%no data
Mahrberg Wealth AG
ARGI Investment Services, LLC
46,836$23.8k0%no data
S&T Bank, Wealth Management Group
38,168$19.4k0%no data
BNY Mellon Asset Management
25,817$13.1k0%no data
Savant Capital, LLC
25,000$12.7k0%no data
WMS Partners, LLC
25,000$12.7k0%no data
Jerome Zeldis
22,917$11.6k0%no data
Susquehanna International Group, LLP, Asset Management Arm
22,849$11.6k0%no data
BlackRock, Inc.
20,204$10.3k-82.67%no data
Delta Investment Management, LLC
Money Concepts International, Inc, Asset Management Arm
17,750$9.0k-26.2%no data
Diane Parks
14,940$7.6k0%no data
Millennium Management LLC
14,588$7.4k11.5%no data
Tower Research Capital LLC
13,385$6.8k56.68%no data
Jonathan Guarino
11,000$5.6k0%no data

Company Information

Soligenix, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Soligenix, Inc.
  • Ticker: SNGX
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$21.872m
  • Shares outstanding: 43.11m
  • Website:

Number of Employees


  • Soligenix, Inc.
  • 29 Emmons Drive
  • Suite B-10
  • Princeton
  • New Jersey
  • 8540
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SNGXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1987
DOA2DB (Deutsche Boerse AG)YesCommon StockDEEURJun 1987

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/23 00:00
End of Day Share Price2022/09/23 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.